Burford Brothers Inc. Raises Holdings in Novo Nordisk A/S $NVO

Burford Brothers Inc. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 7.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,826 shares of the company’s stock after acquiring an additional 745 shares during the quarter. Burford Brothers Inc.’s holdings in Novo Nordisk A/S were worth $747,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. First Hawaiian Bank increased its stake in shares of Novo Nordisk A/S by 0.6% in the first quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock worth $1,556,000 after purchasing an additional 142 shares in the last quarter. Anchor Investment Management LLC boosted its holdings in Novo Nordisk A/S by 1.1% in the 1st quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock worth $944,000 after buying an additional 150 shares during the period. Xponance Inc. grew its stake in Novo Nordisk A/S by 5.0% in the 1st quarter. Xponance Inc. now owns 3,314 shares of the company’s stock valued at $230,000 after buying an additional 158 shares in the last quarter. Foster Dykema Cabot & Partners LLC raised its holdings in Novo Nordisk A/S by 3.8% during the 1st quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock valued at $319,000 after acquiring an additional 166 shares during the period. Finally, Werba Rubin Papier Wealth Management boosted its holdings in shares of Novo Nordisk A/S by 4.1% in the second quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock worth $302,000 after acquiring an additional 173 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 3.0%

Shares of NVO opened at $54.41 on Friday. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $118.26. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The stock has a 50 day simple moving average of $56.24 and a two-hundred day simple moving average of $62.72. The firm has a market cap of $242.93 billion, a P/E ratio of 14.95, a P/E/G ratio of 2.50 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s payout ratio is presently 22.53%.

Analyst Ratings Changes

Several brokerages have commented on NVO. BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price for the company in a research note on Wednesday, August 13th. HSBC set a $70.00 target price on Novo Nordisk A/S in a research note on Wednesday, October 1st. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Finally, Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $76.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.